*** 25 Updates to AMBS Pipeline (Rev. 10/23) ***
Post# of 30066
Posted On: 10/23/2014 12:44:52 PM
*** 25 Updates to AMBS Pipeline (Rev. 10/23) ***
01.) LymPro - 72 Patient LP-002 Clinical Study Enrollment (completed 09/12/14)
2a.) LymPro - LP-002 clinical performance data results (completed 10/09/14)
2b.) LymPro - incl. patients w/ mild AZ, enrollment 68 patient LP-002 exten. (est. 4Q14)
2c.) LymPro - incl. data announced from full cohort 140 subjects shortly thereafter
03.) LymPro - JV Partnership Agreement (est. 4Q14)
04.) LymPro - TBI / CTE update studies
05.) LymPro - Partner valid. of APP & CLIA cert. (est. 4Q14)
06.) Eltoprazine - 200 patient Ph. 2b trial PD-LID (est. 4Q14)
07.) Eltoprazine - US IND filed & apvd. for PD-LID (est. 4Q14)
08.) MANF - Ophthalmological ear toxicology complete data sets (est. 4Q14)
09.) MANF CVRO / CROA Glaucoma - animal data / IND to follow (completed 10/07/14)
10.) MANF / GDNF - Renishaw CED Ph. 2B test trial results (est. 4Q14)
11.) MANF RP - Orphan Drug (ODD) / 30 day FDA apvl. on 11/15 - (completed 10/16/14)
12.) MANF OIS - Ocular Ischemic Syndrome - ODD applic. filed (est. 4Q14)
13.) MANF DB-1 Wolframs - Retinal eye data test results (est. 4Q14)
14.) MANF DB-1 Wolframs - orphan potential (est. 4Q14)
15.) MANF - Good Mfg. Practices (GMP) for 1st in-man studies (est. 4Q14)
16.) PhenoGuard - JV Partnership update potential
17.) PhenoGuard - discovery of 2nd protein family
18.) PhenoGuard - transformed into 1st rationally designed NF discovery platform
19.) PhenoGuard - evaluation of external drug candidates for in-licensure potential
20.) NuroPro - preparing Ph. 2 CLIA validation study
21.) potential - financial engineering
22.) potential - multiple grant funding
23.) potential - new acquisition / Cerora AD scanner
24.) potential - diagnostics div. spin off
25.) NASDAQ up-listing - (est. 4Q14)
***** Note: all above items were abstracted from the 3 following recent sources: *****
a.) AMBS Chairmans Blog, dated 8/10/14
b.) Crystal Research Co. Report, dated 9/8/14
c.) SEC 8-K Filing, dated 10/10/14
d.) 10/09 PR – Item #2b, 2c Rev.
01.) LymPro - 72 Patient LP-002 Clinical Study Enrollment (completed 09/12/14)
2a.) LymPro - LP-002 clinical performance data results (completed 10/09/14)
2b.) LymPro - incl. patients w/ mild AZ, enrollment 68 patient LP-002 exten. (est. 4Q14)
2c.) LymPro - incl. data announced from full cohort 140 subjects shortly thereafter
03.) LymPro - JV Partnership Agreement (est. 4Q14)
04.) LymPro - TBI / CTE update studies
05.) LymPro - Partner valid. of APP & CLIA cert. (est. 4Q14)
06.) Eltoprazine - 200 patient Ph. 2b trial PD-LID (est. 4Q14)
07.) Eltoprazine - US IND filed & apvd. for PD-LID (est. 4Q14)
08.) MANF - Ophthalmological ear toxicology complete data sets (est. 4Q14)
09.) MANF CVRO / CROA Glaucoma - animal data / IND to follow (completed 10/07/14)
10.) MANF / GDNF - Renishaw CED Ph. 2B test trial results (est. 4Q14)
11.) MANF RP - Orphan Drug (ODD) / 30 day FDA apvl. on 11/15 - (completed 10/16/14)
12.) MANF OIS - Ocular Ischemic Syndrome - ODD applic. filed (est. 4Q14)
13.) MANF DB-1 Wolframs - Retinal eye data test results (est. 4Q14)
14.) MANF DB-1 Wolframs - orphan potential (est. 4Q14)
15.) MANF - Good Mfg. Practices (GMP) for 1st in-man studies (est. 4Q14)
16.) PhenoGuard - JV Partnership update potential
17.) PhenoGuard - discovery of 2nd protein family
18.) PhenoGuard - transformed into 1st rationally designed NF discovery platform
19.) PhenoGuard - evaluation of external drug candidates for in-licensure potential
20.) NuroPro - preparing Ph. 2 CLIA validation study
21.) potential - financial engineering
22.) potential - multiple grant funding
23.) potential - new acquisition / Cerora AD scanner
24.) potential - diagnostics div. spin off
25.) NASDAQ up-listing - (est. 4Q14)
***** Note: all above items were abstracted from the 3 following recent sources: *****
a.) AMBS Chairmans Blog, dated 8/10/14
b.) Crystal Research Co. Report, dated 9/8/14
c.) SEC 8-K Filing, dated 10/10/14
d.) 10/09 PR – Item #2b, 2c Rev.
(0)
(0)